RE:Wouldn't get my hopes upand they asked for secondary data because...?
"
2021-09-01 08:47 ET - News Release
Mr. Rob Fia reports
THERMA BRIGHT PROVIDES UPDATE ON FDA-EUA APPLICATION PROCESS
Therma Bright Inc. has provided an update on its AcuVid saliva test with the U.S. Food and Drug Administration's emergency use authorization (EUA) application.
During the past 30 days, the Therma Bright team has been actively engaged with officials at the FDA around our first-of-its-kind AcuVid COVID-19 rapid antigen saliva test and our successful clinical study results," expressed Rob Fia, chief executive officer of Therma Bright. "The team, with support from our U.S. development partners, have successfully completed and submitted additional research and documentation requested by the FDA, and we now await for the administration to complete its review for emergency use authorization."